inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - Æxlishemjandi lyf - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
cinacalcet stada filmuhúðuð tafla 90 mg
stada arzneimittel ag - cinacalcetum hýdróklóríð - filmuhúðuð tafla - 90 mg
cinacalcet wh filmuhúðuð tafla 30 mg
williams & halls ehf. - cinacalcetum hýdróklóríð - filmuhúðuð tafla - 30 mg
cinacalcet stada filmuhúðuð tafla 60 mg
stada arzneimittel ag - cinacalcetum hýdróklóríð - filmuhúðuð tafla - 60 mg
escitalopram bluefish filmuhúðuð tafla 5 mg
bluefish pharmaceuticals ab - escitalopramum oxalat - filmuhúðuð tafla - 5 mg
peratsin húðuð tafla 2 mg
orion corporation - perphenazinum inn - húðuð tafla - 2 mg
darunavir medical valley filmuhúðuð tafla 600 mg
medical valley invest ab - darunavir propylene glycolate - filmuhúðuð tafla - 600 mg
venlafaxin medical valley forðatafla 150 mg
medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 150 mg
bupropion teva tafla með breyttan losunarhraða 300 mg
teva b.v.* - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 300 mg
atropin viatris (atropin mylan) stungulyf, lausn 0,5 mg/ml
viatris limited - atropine sulfate - stungulyf, lausn - 0,5 mg/ml